Your browser doesn't support javascript.
loading
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.
Tsai, Jessica W; Cejas, Paloma; Wang, Dayle K; Patel, Smruti; Wu, David W; Arounleut, Phonepasong; Wei, Xin; Zhou, Ningxuan; Syamala, Sudeepa; Dubois, Frank P B; Crane, Alexander; Pelton, Kristine; Vogelzang, Jayne; Sousa, Cecilia; Baguette, Audrey; Chen, Xiaolong; Condurat, Alexandra L; Dixon-Clarke, Sarah E; Zhou, Kevin N; Lu, Sophie D; Gonzalez, Elizabeth M; Chacon, Madison S; Digiacomo, Jeromy J; Kumbhani, Rushil; Novikov, Dana; Hunter, J'Ya; Tsoli, Maria; Ziegler, David S; Dirksen, Uta; Jager, Natalie; Balasubramanian, Gnana Prakash; Kramm, Christof M; Nathrath, Michaela; Bielack, Stefan; Baker, Suzanne J; Zhang, Jinghui; McFarland, James M; Getz, Gad; Aguet, François; Jabado, Nada; Witt, Olaf; Pfister, Stefan M; Ligon, Keith L; Hovestadt, Volker; Kleinman, Claudia L; Long, Henry; Jones, David T W; Bandopadhayay, Pratiti; Phoenix, Timothy N.
Afiliação
  • Tsai JW; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Cejas P; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
  • Wang DK; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Patel S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Wu DW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, Cancer Program, Broad Institute, Cambridge, Massachusetts.
  • Arounleut P; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Wei X; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Zhou N; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
  • Syamala S; Division of Pediatric Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Dubois FPB; Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Crane A; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Pelton K; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
  • Vogelzang J; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
  • Sousa C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Baguette A; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, Cancer Program, Broad Institute, Cambridge, Massachusetts.
  • Chen X; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Condurat AL; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, Cancer Program, Broad Institute, Cambridge, Massachusetts.
  • Dixon-Clarke SE; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Zhou KN; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lu SD; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Gonzalez EM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chacon MS; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Digiacomo JJ; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Kumbhani R; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Novikov D; Quantitative Life Sciences, McGill University, Montreal, Quebec H3A 2A7, Canada.
  • Hunter J; Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada.
  • Tsoli M; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Ziegler DS; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Dirksen U; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Jager N; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Balasubramanian GP; Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts.
  • Kramm CM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Nathrath M; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Bielack S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Baker SJ; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Zhang J; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • McFarland JM; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Getz G; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Aguet F; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Jabado N; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Witt O; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Pfister SM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Ligon KL; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Hovestadt V; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Kleinman CL; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Long H; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Jones DTW; Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • Bandopadhayay P; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
  • Phoenix TN; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
Cancer Res ; 82(17): 2980-3001, 2022 09 02.
Article em En | MEDLINE | ID: mdl-35802025
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição Forkhead / Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Child / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição Forkhead / Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Child / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article